Laddar...
A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
BACKGROUND. Sorafenib has proven survival benefits in patients with advanced hepatocellular carcinoma (HCC). The viability of continuing sorafenib at a higher dosage in patients who experienced radiologic disease progression was investigated. METHODS. Patients who experienced disease progression whi...
Sparad:
| Huvudupphovsmän: | , , , , , , , , , , , , , , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
AlphaMed Press
2013
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3639524/ https://ncbi.nlm.nih.gov/pubmed/23580239 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0221 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|